Back to Sites

Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS

Site Number

31784

Address

Chiang Mai University Pediatrics-Obstetrics CRS
Chiang Mai University-RIHES
P.O. Box 80 CMU
Chiang Mai, 50202
Thailand

IMPAACT Members at this Site

Supaporn Kaewma Administrative Assistant

Suwat Chariyalertsak CAB Liaison

Nongyow Wongnum Clinical Research Assistant

Chulapong Chanta Co-Investigator

Chanya Dachapratoomwan Co-Investigator

Thira Sirisanthana Co-Investigator

Wipada Cheewawat Community Coordinator

Daralak Tavornprasit CRS Coordinator

Virat Sirisanthana CRS Leader

Khuanchai Supparatpinyo CRS Leader

Kannika Boursuk CRS Staff

Sineenart Nimsakul CTU Coordinator

Chintana Khamrong CTU Principal Investigator

Kiat Ruxrungtham CTU Principal Investigator

Bariatu Smith DAIDS PO

Kantaphat Daechapratoomwan Data Management Staff

Sukrapee Chaiinseeard Data Manager

Jarun Chuayen Data Manager

Tipawal Petthed Data Manager

Kamolrawee Srichan Data Manager

Sineenart Taejaroenkul Data Manager

Antika Wongthanee Data Manager

Venus Kaewyoo Financial Administrator

Surangchit Koottathep Financial Administrator

Henry Lange Financial Administrator

Linda Aurpibul Investigator

David Boulware Investigator

Peninnah Oberdorfer Investigator

Thanyawee Puthanakit Investigator

Pannee Sirivatanapa Investigator

Tavitiya Sudjaritruk Investigator

Rassamee Keawvichit Laboratory Manager/Supervisor

Waraporn Pasawad Laboratory Manager/Supervisor

Kittipong Rungruengthanakit Laboratory Manager/Supervisor

Kanlaya Wongworapat Laboratory Manager/Supervisor

Sunisa Butphet Laboratory Technician

Sirikwan Dokuta Laboratory Technician

Paweena Khamdam Laboratory Technician

Rattana Kunnapa Laboratory Technician

Chamaiporn Naprom Laboratory Technician

Kadsarin Chantan Local Laboratory

Warunee Jit-Aree Local Laboratory

Chiraphorn Kaewkosaba Local Laboratory

Chayanid Maneechai Local Laboratory

Satitpong Nunjai Local Laboratory

Jiraporn Yamano Local Laboratory

Natthaporn Sriboonmak Pediatrician

Piyathida Kunlachanpises Pharmacist

Nataporn Kosachunhanan Pharmacy Technician

Veruree Manoyos Pharmacy Technician

Wirat Niwatananun Pharmacy Technician

Piyathida Sroysuwan Pharmacy Technician

Potchanart Emsiranant Project Director

Oranitcha Kaewthip QA/QC Coordinator

Arawan Larplertsakul QA/QC Coordinator

Umpava Timpan QA/QC Coordinator

Nittaya Chuenchop Regulatory Coordinator

Marisa Guptarak Regulatory Coordinator

Lara Johnson Regulatory Coordinator

Sukanya Linpisarn Regulatory Coordinator

Rachaneekorn Nadsasarn Research Assistant

Worawan Wongjak Research Assistant

Suchada Chaiyarat Research Nurse

Jiraporn Chanthong Research Nurse

Prapaporn Janjing Research Nurse

Kanjana Jeenarach Research Nurse

Pranee Khad-Umong Research Nurse

Sopida Kiattivej Research Nurse

Supunnee Masurin Research Nurse

Atcharawan Sansupa Research Nurse

Saowalak Sarachai Research Nurse

Angkana Srita Research Nurse

Wanvisa Taweehorm Research Nurse

Rattika Thammalangka Research Nurse

Studies at this Site

P1026S: PK in Pregnancy

DAIDS Number

Therapeutics

Research Area

Treatment

Study Status

Closed to Follow Up

P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants

DAIDS Number

10732

Research Area

Tuberculosis

P1081: 3 Regimens for HIV Infected Women initiating ARV regimens for PMTCT

DAIDS Number

10770

Research Area

Mother to child transmission

Study Status

Concluded

P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir

DAIDS Number

11773

Research Area

Therapeutics

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

34150

Research Area

Treatment

Study Status

Concluded

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

38504

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

38637

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2017: MOCHA

DAIDS Number

30070

Research Area

Therapeutics

Study Status

Closed to Accrual

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

DAIDS Number

38932

Research Area

Therapeutics

Study Status

Enrolling